Bold Therapeutics is focused on developing innovative metallotherapeutics, particularly their lead candidate BOLD-100, which is a ruthenium-based small molecule therapeutic. BOLD-100 exhibits a unique multimodal mechanism of action that includes altering the unfolded protein response (UPR) through selective inhibition of GRP78, as well as inducing reactive oxygen species (ROS) that lead to DNA damage and cell cycle arrest. This dual action allows BOLD-100 to effectively target both sensitive and resistant cancer cells, enhancing the efficacy of existing cancer therapies, including traditional chemotherapies and targeted treatments. The compound has shown promising results in clinical trials, particularly in advanced gastrointestinal cancers, and has received Orphan Drug Designations for certain indications.

The company is committed to expanding its pipeline of metallotherapeutics by leveraging its innovative screening platform to identify new compounds with high anticancer activity and low toxicity. Bold Therapeutics collaborates with a global network of academic chemists and clinical partners to advance the development of BOLD-100 and other investigational drugs. Their ongoing clinical trials aim to address significant unmet needs in cancer treatment, particularly for patients with advanced metastatic colorectal, gastric, and biliary tract cancers. The promising preclinical and clinical data suggest that BOLD-100 could significantly improve patient outcomes and provide new therapeutic options in oncology.

Canada

Bold Therapeutics is the world leader in the development of novel metallotherapeutics. Bold Therapeutics' lead program, BOLD-100, has demonstrated positive safety and efficacy in Phase 2 clinical trials in colorectal, biliary tract and gastric cancers, with presentations at ASCO 2024 and ASCO GI 2024. Bold Therapeutics expects to initiate pivotal Phase 3 trials in the near future.

Bold Therapeutics

Company Details